TIDMAGL
Angle PLC
11 February 2020
For immediate release 11 February 2020
ANGLE plc ("the Company")
NEW STUDY DEMONSTRATES POTENTIAL FOR PARSORTIX IN MELANOMA
PROGNOSTICATION AND TREATMENT RESPONSE
Parsortix out-performed alternative systems in head to head
comparisons and was selected for molecular analysis in the
study
Parsortix CTC score linked to progression-free and overall
survival of patients
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that a customer, the Edith Cowan
University in Perth, Western Australia has published results of
research into the use of ANGLE's Parsortix(R) system with melanoma
patients.
The research shows that the Parsortix system can be used to
investigate the heterogeneity of the cancer allowing full molecular
analysis of the cancer. The researchers believe this opens the
potential for liquid biopsy to be used for prognostication
(assessing prognosis) and treatment response monitoring in
melanoma.
In a pilot study of 28 melanoma patients, those with circulating
tumour cells (CTCs) present in their blood, harvested by Parsortix,
had significantly shorter overall survival with a hazard ratio of
7.8x meaning that patients with a positive Parsortix CTC score were
7.8x more likely to die during a 60 week follow-up period than
those with a negative CTC score. In clinical use, the
stratification of patients into high and low risk groups may allow
improved treatment decisions, taking into account disease
status.
The research also compared results from the Parsortix system
with some competing systems using matched samples and determined
that Parsortix yielded the highest recovery of CTCs and had lower
white blood cell background. The Parsortix system also did not
require pre-processing of the blood whereas the competing systems
required a number of pre-processing steps to be undertaken manually
to remove red blood cells prior to processing.
The research has been published as a peer-reviewed publication
in the British Journal of Cancer and is available at
https://angleplc.com/library/publications/.
Elin Gray, Associate Professor, Melanoma Research Group, School
of Medical and Health Sciences, Edith Cowan University, Western
Australia, commented:
"This work clearly demonstrates the promising clinical utility
of the Parsortix system for metastatic melanoma prognostication and
monitoring treatment response. We now intend to progress our work
with Parsortix to identify ways in which we can improve the
treatment of melanoma patients."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is another great example of one of our customers
developing new pilot studies to show the potential clinical utility
of Parsortix in other cancer types and applications. Melanoma is an
important opportunity for future use of Parsortix."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include an epitope-independent circulating tumor cell
(CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and
proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple downstream subsequent analyses. CTCs enable
the complete picture of a cancer to be seen as they allow DNA, RNA
and protein analysis and the live cells harvested can be cultured.
The Parsortix technology is the subject of 24 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United
States with a 400 subject study in metastatic breast cancer. ANGLE
is seeking to be the first ever FDA cleared CTC harvesting system
and only the third ever FDA cleared liquid biopsy test. ANGLE has
already undertaken two separate 200 subject clinical studies under
a program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is ideal for measuring
gene expression and other markers directly from Parsortix harvests
and was used in the ovarian cancer pelvic mass triage test to
achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
27 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEANAEFAAEEFA
(END) Dow Jones Newswires
February 11, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Angle (LSE:AGL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Angle (LSE:AGL)
Storico
Da Apr 2023 a Apr 2024